Search Results

There are 17847 results for: content related to: Risk of myocardial infarction associated with selective COX-2 inhibitors: Meta-analysis of randomised controlled trials

  1. Cardiovascular and Gastrointestinal Safety of NSAIDs: A Systematic Review of Meta-Analyses of Randomized Clinical Trials

    Clinical Pharmacology & Therapeutics

    Volume 89, Issue 6, June 2011, Pages: 855–866, F Salvo, A Fourrier-Réglat, F Bazin, P Robinson, N Riera-Guardia, M Haag, AP Caputi, N Moore, MC Sturkenboom, A Pariente and on behalf of investigators of the Safety of Non-Steroidal Anti-Inflammatory Drugs: The SOS Project

    Version of Record online : 6 APR 2011, DOI: 10.1038/clpt.2011.45

  2. You have free access to this content
    Defects in mouse nephrogenesis induced by selective and non-selective cyclooxygenase-2 inhibitors

    British Journal of Pharmacology

    Volume 163, Issue 5, July 2011, Pages: 927–936, Anke Olliges, Stefanie Wimmer and Rolf M Nüsing

    Version of Record online : 8 JUN 2011, DOI: 10.1111/j.1476-5381.2011.01313.x

  3. Effect of paracetamol and coxib with or without dexamethasone after laparoscopic cholecystectomy

    Acta Anaesthesiologica Scandinavica

    Volume 52, Issue 5, May 2008, Pages: 673–680, E. TIIPPANA, M. BACHMANN, E. KALSO and P. PERE

    Version of Record online : 15 APR 2008, DOI: 10.1111/j.1399-6576.2008.01650.x

  4. NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib

    Pharmacoepidemiology and Drug Safety

    Volume 18, Issue 12, December 2009, Pages: 1134–1142, Sebastian Schneeweiss, Robert J. Glynn, Jerry Avorn, Muhammad Mamdani, Helen Mogun and Daniel H. Solomon

    Version of Record online : 20 OCT 2009, DOI: 10.1002/pds.1826

  5. You have free access to this content
    The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor

    Alimentary Pharmacology & Therapeutics

    Volume 17, Issue 4, February 2003, Pages: 489–501, S. Alsalameh, M. Burian, G. Mahr, B. G. Woodcock and G. Geisslinger

    Version of Record online : 5 MAR 2003, DOI: 10.1046/j.1365-2036.2003.01460.x

  6. Valdecoxib, a COX-2-Specific Inhibitor, Does Not Affect Cardiac Repolarization

    The Journal of Clinical Pharmacology

    Volume 43, Issue 9, September 2003, Pages: 974–982, Dr Nenad Sarapa, Dr Margaret R. Britto, Ms Barbara Cotton, Dr Steven R. Cox, Dr Steven F. Francom, Ms Na Jin, Dr Emery D. Polasek, Dr Stephen M. Sainati, Ms Sharon L. Crosby-Sessoms and Dr Joseph C. Fleishaker

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270003257220

  7. Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials

    Journal of Clinical Pharmacy and Therapeutics

    Volume 31, Issue 6, December 2006, Pages: 565–576, L-C. Chen and D. M. Ashcroft

    Version of Record online : 24 NOV 2006, DOI: 10.1111/j.1365-2710.2006.00774.x

  8. A liquid chromatography–mass spectrometry method for the quantification of both etoricoxib and valdecoxib in human plasma

    Biomedical Chromatography

    Volume 19, Issue 2, March 2005, Pages: 113–118, Ulrike Werner, Dierk Werner, Burkhard Hinz, Christoph Lambrecht and Kay Brune

    Version of Record online : 7 OCT 2004, DOI: 10.1002/bmc.423

  9. You have free access to this content
    Arthritis & Rheumatism, 2001 Annual Scientific Meeting Abstracts, November 10–15, 2001, San Francisco, CA

    Arthritis & Rheumatism

    Volume 44, Issue S9, September 2001, Pages: 277–390,

    Version of Record online : 22 FEB 2002, DOI: 10.1002/1529-0131(200109)44:9+<::AID-ART427>3.0.CO;2-4

  10. Cardiovascular Risks of Cyclooxygenase Inhibition

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 26, Issue 7, July 2006, Pages: 919–938, Dr. Zachary A. Stacy, Dr. Paul P. Dobesh and Dr. Toby C. Trujillo

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.26.7.919

  11. You have free access to this content
    Valdecoxib for Treatment of Primary Dysmenorrhea

    Journal of General Internal Medicine

    Volume 20, Issue 1, January 2005, Pages: 62–67, Stephen E. Daniels, Sarah Torri and Paul J. Desjardins

    Version of Record online : 7 JAN 2005, DOI: 10.1111/j.1525-1497.2004.30052.x

  12. Utility and Sensitivity of the Sore Throat Pain Model: Results of a Randomized Controlled Trial on the COX-2 Selective Inhibitor Valdecoxib

    The Journal of Clinical Pharmacology

    Volume 47, Issue 7, July 2007, Pages: 860–870, Dr Bernard P. Schachtel, Dr Sharon Pan, Dr Joseph D. Kohles, Ms Kathleen M. Sanner, Dr Emily P. Schachtel and Ms Mary Bey

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007301621

  13. You have free access to this content
    Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: Case study of cyclooxygenase 2–selective inhibitors for the treatment of osteoarthritis

    Arthritis Care & Research

    Volume 53, Issue 4, 15 August 2005, Pages: 510–518, Chin Lee, Elke Hunsche, Robert Balshaw, Sheldon X. Kong and Thomas J. Schnitzer

    Version of Record online : 4 AUG 2005, DOI: 10.1002/art.21328

  14. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events–stroke, acute myocardial infarction, and death from coronary heart disease

    Pharmacoepidemiology and Drug Safety

    Volume 18, Issue 11, November 2009, Pages: 1053–1063, Christianne L. Roumie, Neesha N. Choma, Lisa Kaltenbach, Edward F. Mitchel, Jr, Patrick G. Arbogast and Marie R. Griffin

    Version of Record online : 27 JUL 2009, DOI: 10.1002/pds.1820

  15. The COX-2 Selective Inhibitor, Valdecoxib, Does Not Impair Platelet Function in the Elderly: Results of a Randomized Controlled Trial

    The Journal of Clinical Pharmacology

    Volume 43, Issue 5, May 2003, Pages: 504–513, Dr. Philip T. Leese, Dr. David P. Recker and Dr. Jeffrey D. Kent

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270003252234

  16. You have free access to this content
    Adherence to gastroprotection during cyclooxygenase 2 inhibitor treatment and the risk of upper gastrointestinal tract events: A population-based study

    Arthritis & Rheumatism

    Volume 64, Issue 8, August 2012, Pages: 2792–2802, Vera E. Valkhoff, Eva M. van Soest, Giampiero Mazzaglia, Mariam Molokhia, René Schade, Gianluca Trifiro, Jay L. Goldstein, Sonia Hernandez-Diaz, Ernst J. Kuipers and Miriam C. J. M. Sturkenboom

    Version of Record online : 27 JUL 2012, DOI: 10.1002/art.34433

  17. You have free access to this content
    Selective cyclooxygenase 2 inhibitors and cardiovascular events

    Arthritis & Rheumatism

    Volume 52, Issue 7, July 2005, Pages: 1968–1978, Daniel H. Solomon

    Version of Record online : 28 JUN 2005, DOI: 10.1002/art.21132

  18. NSAID Action and the Foundations for Cardiovascular Toxicity

    Cardiotoxicity of Non-Cardiovascular Drugs

    Anna L. Blobaum, Lawrence J. Marnett, Pages: 257–285, 2010

    Published Online : 9 APR 2010, DOI: 10.1002/9780470660379.ch8

  19. You have free access to this content
    Effect of nonsteroidal antiinflammatory drugs on the C-reactive protein level in rheumatoid arthritis: A meta-analysis of randomized controlled trials

    Arthritis & Rheumatism

    Volume 64, Issue 11, November 2012, Pages: 3511–3521, Simon Tarp, Else M. Bartels, Henning Bliddal, Daniel E. Furst, Maarten Boers, Bente Danneskiold-Samsøe, Mette Rasmussen and Robin Christensen

    Version of Record online : 27 OCT 2012, DOI: 10.1002/art.34644

  20. You have free access to this content
    Prescriptions for Chronic High-Dose Cyclooxygenase-2 Inhibitors are Often Inappropriate and Potentially Dangerous

    Journal of General Internal Medicine

    Volume 20, Issue 10, October 2005, Pages: 879–883, Christianne L. Roumie, Patrick G. Arbogast, Edward F. Mitchel Jr. and Marie R. Griffin

    Version of Record online : 14 JUL 2005, DOI: 10.1111/j.1525-1497.2005.0173.x